Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 4 Major Bleeding With Concurrent Use of GP IIb/IIIa Antagonists and Pretreatment With Clopidogrel
Major bleeding in relation to concurrent use of glycoprotein (GP) IIb/IIIa antagonists and clopidogrel pretreatment at least 6 h before percutaneous coronary intervention (PCI). Major bleeding was significantly reduced with fondaparinux (yellow) compared with enoxaparin (red) with or without concurrent use of these antiplatelet agents. GP IIb/IIIa (+) = GP IIb/IIIa inhibitor used before/during PCI; GP IIb/IIIa (–) = GP IIb/IIIa inhibitor not used before/during PCI; clopidogrel (+) = clopidogrel given at least 6 h before PCI; clopidogrel (–) = clopidogrel not given at least 6 h before PCI. CI = confidence interval; HR = hazard ratio.
|
